BAROnova, Inc., is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.

    BAROnova® recently closed a Series D financing of $36.5 million to continue the clinical development of the TransPyloric Shuttle® weight-loss system.* This technology focuses on potentially slowing a person’s gastric emptying, which is a known mechanism of action for weight loss.  In December 2015, BAROnova began enrolling patients in the ENDObesity® II Study, a twelve-month multicenter pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle.